Sales & Support: 314-485-5210



Catalogue number:
250 mg
Product is available in:
  • USA
  • Canada
$160.00 Shipping is calculated in checkout

Immunosuppressant; DHODH inhibitor. Inhibits Sars-CoV-2 in cells, possibly through UTP depletion. Xiong et al. bioRxiv, Mar 12 2020, https://doi.org/10.1101/2020.03.11.983056.

  • Datasheet:   view or download
  • Applications:Approved drug (U.S.); in COVID-19 clinical trials
Product Type:

Biochemicals & reagents

CAS Number:



1) Teschner et al. (2010), Leflunomide: a drug with a potential beyond rheumatology; Immunotherapy, 2 637 2) Davis et al. (1996), The immunosuppressive metabolite of leflunomide is a potent inhibitor of human dihydroorotate dehydrogenase; Biochemistry, 35 1270 3) Latchoumycandane et al. (2007), Mitochondrial protection by the JNK ninhibitor leflunomide rescues mice from acetaminophen-induced liver injury; Hepatology, 45 412

Limit of Detection:


Storage Temperature:

Room Temperature

Additional Information:

Leflunomide is a pyrimidine biosynthesis inhibitor DMARD (disease-modifying antirheumatic drug) (1) which also displays immunomodulatory activity inhibiting the mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) (2), although the molecule directly responsible for DHODH is actually A77 1726, a metabolite of Leflunomide. This compound also rescues mice from acetaminophen-induced liver injury (3).